Perspective Therapeutics

Update in progress

CATX (NYSE American)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on precision targeted alpha therapies (TAT) for cancer. It develops VMT-a-NET for unresectable or metastatic SSTR2-expressing neuroendocrine tumors (Phase 1/2a), VMT01 for MC1R-positive metastatic melanoma (Phase 1/2a), and PSV359 targeting fibroblast activation protein alpha. It also develops Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer and collaborates with Bristol Myers Squibb on [212Pb] VMT01 with nivolumab. Formerly Isoray, renamed 2022. Founded 2004, Seattle.

Company score

Sentiment: 0.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive